How to treat chronic myeloid leukemia (CML) in older adults

被引：9

作者：

Luskin, Marlise R. ^{[1
]}

DeAngelo, Daniel J. ^{[2
]}

机构：

[1] Dana Farber Canc Inst, 450 Brookline Ave,Dana 2056, Boston, MA 02215 USA

[2] Harvard Med Sch, Inst Phys, Dana Farber Canc Inst, Clin & Translat Res,Adult Leukemia Program, 450 Brookline Ave, Boston, MA 02215 USA

来源：

JOURNAL OF GERIATRIC ONCOLOGY | 2018年 / 9卷 / 04期

关键词：

Chronic myeloid leukemia; Geriatric oncology; Targeted therapy; Tyrosine kinase inhibitors; Quality of life; CHRONIC MYELOGENOUS LEUKEMIA; ARTERIAL OCCLUSIVE DISEASE; BONE-MARROW-TRANSPLANTATION; TYROSINE KINASE INHIBITORS; MEDICARE PART D; CHRONIC-PHASE; ELDERLY-PATIENTS; PLEURAL EFFUSIONS; NILOTINIB THERAPY; FOLLOW-UP;

D O I：

10.1016/j.jgo.2018.01.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukemia (CML), a myeloproliferative neoplasm defined by the t(9;22)(q34;q11) chromosomal translocation, primarily affects older adults. Historically, effective treatment options were not available for older CML patients ineligible for curative allogeneic stem cell transplant, and the disease was therefore usually fatal within several years of diagnosis. The development of tyrosine kinase inhibitors (TKIs) that effectively target the constitutively active mutant tyrosine kinase in CML has dramatically improved outcomes for all patients with CML, including older patients. While older patients were underrepresented in prospective trials, TKI therapy can be successfully administered to older adults with CML with excellent efficacy and proven tolerability. TKI selection and monitoring for adverse events should be tailored based on co-morbidities. As with younger patients, life expectancy of older adults with CML now approaches that of age-matched controls. Here we review guidelines for management of older adults with CML. (C) 2018 Elsevier Ltd. All rights reserved.

引用

页码：291 / 295

页数：5

共 70 条

[1] Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML [J].

Aichberger, Karl J. ;

Herndlhofer, Susanne ;

Schernthaner, Gerit-Holger ;

Schillinger, Martin ;

Mitterbauer-Hohendanner, Gerlinde ;

Sillaber, Christian ;

Valent, Peter .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (07) :533-539

[2] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[3]

BIGGS JC, 1992, BLOOD, V80, P1352

[4] Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008 [J].

Bjorkholm, Magnus ;

Ohm, Lotta ;

Eloranta, Sandra ;

Derolf, Asa ;

Hultcrantz, Malin ;

Sjoberg, Jan ;

Andersson, Therese ;

Hoglund, Martin ;

Richter, Johan ;

Landgren, Ola ;

Kristinsson, Sigurdur Y. ;

Dickman, Paul W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) :2514-2520

[5] Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [J].

Bower, Hannah ;

Bjorkholm, Magnus ;

Dickman, Paul W. ;

Hoglund, Martin ;

Lambert, Paul C. ;

Andersson, Therese M. -L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2851-+

[6] Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib [J].

Breccia, Massimo ;

Latagliata, Roberto ;

Stagno, Fabio ;

Luciano, Luigiana ;

Gozzini, Antonella ;

Castagnetti, Fausto ;

Fava, Carmen ;

Cavazzini, Francesco ;

Annunziata, Mario ;

Rossi, Antonella Russo ;

Pregno, Patrizia ;

Abruzzese, Elisabetta ;

Vigneri, Paolo ;

Rege-Cambrin, Giovanna ;

Sica, Simona ;

Pane, Fabrizio ;

Santini, Valeria ;

Specchia, Giorgina ;

Rosti, Gianantonio ;

Alimena, Giuliana .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (10) :1457-1461

[7] De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial [J].

Clark, Richard E. ;

Polydoros, Fotios ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Pocock, Christopher ;

Smith, Graeme ;

Byrne, Jenny L. ;

de lavallade, Hugues ;

O'Brien, Stephen G. ;

Coffey, Tony ;

Foroni, Letizia ;

Copland, Mhairi .

LANCET HAEMATOLOGY, 2017, 4 (07) :E310-E316

[8] A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias [J].

Cortes, J. E. ;

Kim, D. -W. ;

Pinilla-Ibarz, J. ;

le Coutre, P. ;

Paquette, R. ;

Chuah, C. ;

Nicolini, F. E. ;

Apperley, J. F. ;

Khoury, H. J. ;

Talpaz, M. ;

DiPersio, J. ;

DeAngelo, D. J. ;

Abruzzese, E. ;

Rea, D. ;

Baccarani, M. ;

Mueller, M. C. ;

Gambacorti-Passerini, C. ;

Wong, S. ;

Lustgarten, S. ;

Rivera, V. M. ;

Clackson, T. ;

Turner, C. D. ;

Haluska, F. G. ;

Guilhot, F. ;

Deininger, M. W. ;

Hochhaus, A. ;

Hughes, T. ;

Goldman, J. M. ;

Shah, N. P. ;

Kantarjian, H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (19) :1783-1796

[9] Chronic myeloid leukemia: sequencing of TKI therapies [J].

Cortes, Jorge ;

Kantarjian, Hagop .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :164-169

[10] How I treat newly diagnosed chronic phase CML [J].

Cortes, Jorge ;

Kantarjian, Hagop .

BLOOD, 2012, 120 (07) :1390-1397

← 1 2 3 4 5 6 7 →